|
|
PERPUSTAKAAN SEKOLAH TINGGI ILMU KESEHATAN SAMARINDA REPOSITORY
|
|
Select Language
Simple Search
Advanced Search
License
This Software is Released Under GNU GPL License
Version 3.
indexed
Visitors
Statistic
|
| Title |
Asian Journal of Pharmaceutical Sciences Volume 19, Issue 2 2024 |
| Edition |
Volume 19, Issue 2 2024 |
| Call Number |
|
| ISBN/ISSN |
|
| Author(s) |
|
| Subject(s) |
Nanomedicine Tumor reprogramming
|
| Classification |
|
| Series Title |
|
GMD |
Jurnal |
| Language |
Indonesia |
| Publisher |
China Medical University |
| Publishing Year |
2024 |
| Publishing Place |
China |
| Collation |
|
| Abstract/Notes |
a b s t r a c t
With the rapid development of the fields of tumor biology and immunology, tumor
immunotherapy has been used in clinical practice and has demonstrated significant
therapeutic potential, particularly for treating tumors that do not respond to standard
treatment options. Despite its advances, immunotherapy still has limitations, such as
poor clinical response rates and differences in individual patient responses, largely
because tumor tissues have strong immunosuppressive microenvironments. Many tumors
have a tumor microenvironment (TME) that is characterized by hypoxia, low pH, and
substantial numbers of immunosuppressive cells, and these are the main factors limiting
the efficacy of antitumor immunotherapy. The TME is crucial to the occurrence, growth,
and metastasis of tumors. Therefore, numerous studies have been devoted to improving
the effects of immunotherapy by remodeling the TME. Effective regulation of the TME and
reversal of immunosuppressive conditions are effective strategies for improving tumor
immunotherapy. The use of multidrug combinations to improve the TME is an efficient
way to enhance antitumor immune efficacy. However, the inability to effectively target
drugs decreases therapeutic effects and causes toxic side effects. Nanodrug delivery carriers
have the advantageous ability to enhance drug bioavailability and improve drug targeting.
Importantly,they can also regulate the TME and deliver large or small therapeutic molecules
to decrease the inhibitory effect of the TME on immune cells. Therefore, nanomedicine has
great potential for reprogramming immunosuppressive microenvironments and represents
a new immunotherapeutic strategy. Therefore, this article reviews strategies for improving
the TME and summarizes research on synergistic nanomedicine approaches that enhance
the efficacy of tumor immunotherapy. |
| Specific Detail Info |
|
| Image |
 |
| File Attachment |
LOADING LIST... |
| Availability |
LOADING LIST... |
| |
Back To Previous |
|